EDAN(SZ:300206)2022-12-03 09:56Group 1: Company Overview and Investor Relations - The company, Shenzhen Libang Precision Instrument Co., Ltd., held an investor relations activity on May 16, 2018, including a site visit and product demonstration [1][2][3]. Group 2: Financial Performance - In 2017, the company achieved a revenue of 843 million CNY, representing a year-on-year growth of 20.81% [3][4]. - Domestic sales accounted for 352 million CNY, which is 41.78% of total revenue, with a growth of 32.62% year-on-year [3]. - The in-vitro diagnostic (IVD) product line revenue reached 80.11 million CNY, marking a significant increase of 56.87% year-on-year [6][7]. - In Q1 2018, the company reported a revenue of 233 million CNY, a year-on-year increase of 17.05% [4]. Group 3: Strategic Developments - In October 2017, the company acquired 100% of Sulis Healthcare Products Ltd., now known as Edan Medical (UK) Limited, to expand its direct sales activities in Europe [5]. - The subsidiary, Smart Health, generated a revenue of 7.21 million CNY in 2017, with a positive cash flow, indicating significant operational improvement [6]. Group 4: Market Trends and Opportunities - The global POCT (Point-of-Care Testing) market is expected to grow at a compound annual growth rate (CAGR) of approximately 8%, potentially reaching 24 billion USD in three years [6]. - The company has been increasing its investment in POCT research and development since 2009, with a strategic focus on expanding its product offerings [7]. Group 5: Challenges and Management Focus - In 2017, the company faced challenges with external sales, achieving 491 million CNY in foreign sales, impacted by significant currency depreciation [8]. - The company incurred a foreign exchange loss of 27.29 million CNY due to international market fluctuations [8]. - Management plans to enhance internal controls and cost management to improve operational efficiency and profitability [9].